FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
GlobeNewswire
· *Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new..